Cardiff Oncology (CRDF) Stock Statistics & Valuation Metrics

Cardiff Oncology has a market cap or net worth of $60.17M. The enterprise value is $65.32.

Cardiff Oncology has 68,369,896 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cardiff Oncology’s return on equity (ROE) is -1.01 and return on invested capital (ROIC) is -105.93%.

The current PE Ratio of Cardiff Oncology is ―. Cardiff Oncology’s PEG ratio is 0.15.

In the last 12 months, Cardiff Oncology had revenue of 593.00K and earned -45.85M in profits. Earnings per share was -0.69.

In the last 12 months, operating cash flow was -37.42M and capital expenditures -44.00K, giving a free cash flow of -37.46M billion.

Cardiff Oncology pays an annual dividend of ―, resulting in a dividend yield of ―

Cardiff Oncology upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Cardiff Oncology as a current ratio of 3.67, with Debt / Equity ratio of 1.86%

In the past 12 months, Cardiff Oncology has paid 0.00 in taxes.

Cardiff Oncology EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -4.51.

Cardiff Oncology has $46.06M in cash and marketable securities with $646.00K in debt, giving a net cash position of $45.41M billion.

Gross margin is -2105.71%, with operating margin of -8256.32%, and net profit margin of -7732.04%.

The average price target for Cardiff Oncology is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy